COMMUNIQUÉS West-GlobeNewswire
-
Olema Oncology Announces Departure of Chief Operating and Financial Officer
30/01/2026 -
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
30/01/2026 -
Dr. Linette Williamson Expands Integrative Medicine Services in Encinitas With Physician-Supervised Ozone Sauna Therapy
30/01/2026 -
CrazyBulk: SARM Alternatives for Bulking, Strength and Performance or Just Hype?
30/01/2026 -
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
30/01/2026 -
Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
30/01/2026 -
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
30/01/2026 -
IO Biotech Provides Corporate Update
30/01/2026 -
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
30/01/2026 -
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/01/2026 -
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
30/01/2026 -
Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy
30/01/2026 -
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
30/01/2026 -
Avicanna Announces Medical Cannabis Real World Evidence Results and Publication
30/01/2026 -
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
30/01/2026 -
Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations
30/01/2026 -
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
30/01/2026 -
Immunocore announces R&D leadership evolution
30/01/2026 -
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
30/01/2026
Pages